{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,16]],"date-time":"2025-09-16T17:22:34Z","timestamp":1758043354657,"version":"3.44.0"},"reference-count":24,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,9,12]],"date-time":"2025-09-12T00:00:00Z","timestamp":1757635200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Cardiovasc. Med."],"abstract":"Background<\/jats:title>Sodium-glucose co-transporter 2 inhibitors (SGLT2i) have emerged as a promising treatment for heart failure and cardiomyopathy. Furthermore, recent research has explored the use of SGLT2i in patients with dilated cardiomyopathy (DCM). However, the evidence that SGLT2i can improve left ventricular function and reduce symptoms of heart failure in DCM patients is limited.<\/jats:p><\/jats:sec>Objective<\/jats:title>The objective of our study was to assess the efficacy and safety of SGLT2i in managing DCM patients with heart failure and to predict its effectiveness in DCM patients without heart failure. The benefits of SGLT2i alone or in combination will also be determined.<\/jats:p><\/jats:sec>Methods<\/jats:title>A structured search of bibliographic databases (PubMed, Embase, and the Cochrane Central Register of Controlled Trials) will be undertaken to retrieve randomized controlled trials and cohorts that describe the efficacy and safety of SGLT2i as a major therapy strategy for DCM patients. To ensure that all relevant data were captured, the search did not contain any restrictions on language or publication time. Primary efficacy outcomes will be all-causes mortality and cardiovascular mortality. Primary safety outcomes will be the incidence of hypoglycemia, liver and renal injuries, and recurrent respiratory tract infections. After deduplication, citations will be screened independently by 2 authors, and selected for inclusion based on prespecified criteria. Data extraction and risk of bias assessment will be performed independently and in duplicate.<\/jats:p><\/jats:sec>Conclusions<\/jats:title>This study could potentially provide new insights into the therapeutic strategies for dilated cardiomyopathy patients and reforming clinical guidelines for using SGLT2i to ensure patient safety and medicine efficacy.\n<\/jats:p><\/jats:sec>Trial Registration<\/jats:title>PROSPERO CRD42023417892.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fcvm.2025.1575493","type":"journal-article","created":{"date-parts":[[2025,9,12]],"date-time":"2025-09-12T05:34:56Z","timestamp":1757655296000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Safety and efficacy of SGLT2i administration in dilated cardiomyopathy: protocol for a systematic review and meta-analysis"],"prefix":"10.3389","volume":"12","author":[{"given":"Ruolan","family":"Hu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Li","family":"Yu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jinrong","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lei","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yifei","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2025,9,12]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1161\/CIRCRESAHA.116.309396","article-title":"Dilated cardiomyopathy: genetic determinants and mechanisms","volume":"121","author":"Mcnally","year":"2017","journal-title":"Circ Res"},{"key":"B2","doi-asserted-by":"publisher","first-page":"E263","DOI":"10.1016\/j.jacc.2021.12.012","article-title":"2022 AHA\/ACC\/HFSA guideline for the management of heart failure: a report of the American College of Cardiology\/American Heart Association joint committee on clinical practice guidelines","volume":"79","author":"Heidenreich","year":"2022","journal-title":"J Am Coll Cardiol"},{"key":"B3","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1038\/s41569-024-01074-2","article-title":"Pathophysiology of dilated cardiomyopathy: from mechanisms to precision medicine","volume":"22","author":"Gigli","year":"2025","journal-title":"Nat Rev Cardiol"},{"key":"B4","doi-asserted-by":"publisher","first-page":"281","DOI":"10.14740\/cr1653","article-title":"Efficacy of Beta-blockers and angiotensin-converting enzyme inhibitors in non-ischemic dilated cardiomyopathy: a systematic review and meta-analysis","volume":"15","author":"Llerena-Velastegui","year":"2024","journal-title":"Cardiol Res"},{"key":"B5","doi-asserted-by":"publisher","first-page":"737","DOI":"10.21470\/1678-9741-2021-0562","article-title":"Mechanical circulatory assist devices: which is the best device as bridge to heart transplantation?","volume":"37","author":"Hette","year":"2022","journal-title":"Braz J Cardiovasc Surg"},{"key":"B6","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1002\/ehf2.14188","article-title":"Sglt2 inhibitor therapy for transthyretin amyloid cardiomyopathy: early tolerance and clinical response to dapagliflozin","volume":"10","author":"Dobner","year":"2023","journal-title":"ESC Heart Fail"},{"key":"B7","doi-asserted-by":"publisher","first-page":"110072","DOI":"10.1016\/j.intimp.2023.110072","article-title":"New insights into the molecular mechanisms of Sglt2 inhibitors on ventricular remodeling","volume":"118","author":"Chen","year":"2023","journal-title":"Int Immunopharmacol"},{"key":"B8","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1001\/jamacardio.2023.1266","article-title":"Contemporary use of sodium-glucose cotransporter-2 inhibitor therapy among patients hospitalized for heart failure with reduced ejection fraction in the US: the get with the guidelines-heart failure registry","volume":"8","author":"Pierce","year":"2023","journal-title":"JAMA Cardiol"},{"key":"B9","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1161\/CIRCULATIONAHA.122.063263","article-title":"Racial differences in quality of life in patients with heart failure treated with sodium-glucose cotransporter 2 inhibitors: a patient-level meta-analysis of the chief-hf, define-hf, and preserved-hf trials","volume":"148","author":"Gupta","year":"2023","journal-title":"Circulation"},{"key":"B10","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1007\/s00395-022-00934-7","article-title":"Cardioprotection by selective sglt-2 inhibitors in a non-diabetic mouse model of myocardial ischemia\/reperfusion injury: a class or A drug effect?","volume":"117","author":"Nikolaou","year":"2022","journal-title":"Basic Res Cardiol"},{"key":"B11","doi-asserted-by":"publisher","first-page":"2500","DOI":"10.3390\/antiox11122500","article-title":"The importance of sglt-2 inhibitors as both the prevention and the treatment of diabetic cardiomyopathy","volume":"11","author":"Kowalska","year":"2022","journal-title":"Antioxidants (Basel)"},{"key":"B12","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1007\/s10741-017-9665-9","article-title":"Direct cardiovascular impact of Sglt2 inhibitors: mechanisms and effects","volume":"23","author":"Kaplan","year":"2018","journal-title":"Heart Fail Rev"},{"key":"B13","doi-asserted-by":"publisher","first-page":"2297","DOI":"10.1002\/ejhf.2707","article-title":"Effects of empagliflozin on cardiovascular and renal outcomes in heart failure with reduced ejection fraction according to age: a secondary analysis of emperor-reduced","volume":"24","author":"Filippatos","year":"2022","journal-title":"Eur J Heart Fail"},{"key":"B14","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.1056\/NEJMoa2107038","article-title":"Empagliflozin in heart failure with A preserved ejection fraction","volume":"385","author":"Anker","year":"2021","journal-title":"N Engl J Med"},{"key":"B15","doi-asserted-by":"publisher","first-page":"1028","DOI":"10.1161\/CIRCULATIONAHA.120.045691","article-title":"Empagliflozin in heart failure: diuretic and cardiorenal effects","volume":"142","author":"Griffin","year":"2020","journal-title":"Circulation"},{"key":"B16","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","article-title":"Dapagliflozin in patients with heart failure and reduced ejection fraction","volume":"381","author":"Mcmurray","year":"2019","journal-title":"N Engl J Med"},{"key":"B17","doi-asserted-by":"publisher","first-page":"2900","DOI":"10.2337\/dc22-0614","article-title":"Prescription patterns of cardiovascular- and kidney-protective therapies among patients with type 2 diabetes and chronic kidney disease","volume":"45","author":"Lamprea-Montealegre","year":"2022","journal-title":"Diabetes Care"},{"key":"B18","doi-asserted-by":"publisher","first-page":"4775","DOI":"10.2147\/DDDT.S269514","article-title":"Sglt2 inhibitors: a novel player in the treatment and prevention of diabetic cardiomyopathy","volume":"14","author":"Li","year":"2020","journal-title":"Drug Des Devel Ther"},{"key":"B19","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/2046-4053-4-1","article-title":"Preferred reporting items for systematic review and meta-analysis protocols (prisma-P) 2015 statement","volume":"4","author":"Moher","year":"2015","journal-title":"Syst Rev"},{"key":"B20","doi-asserted-by":"publisher","first-page":"1461","DOI":"10.1007\/s00210-023-02409-5","article-title":"Dapagliflozin protects against dilated cardiomyopathy progression by targeting Nlrp3 inflammasome activation","volume":"396","author":"Hu","year":"2023","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"B21","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1056\/NEJMoa2022190","article-title":"Cardiovascular and renal outcomes with empagliflozin in heart failure","volume":"383","author":"Packer","year":"2020","journal-title":"N Engl J Med"},{"key":"B22","doi-asserted-by":"publisher","first-page":"E37579","DOI":"10.1097\/MD.0000000000037579","article-title":"Effect of dapagliflozin on left ventricular structure and function in patients with non-ischemic dilated cardiomyopathy: an observational study","volume":"103","author":"Hong","year":"2024","journal-title":"Medicine (Baltimore)"},{"key":"B23","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1186\/s43044-024-00508-z","article-title":"Ventricular remodeling and hemodynamic changes in heart failure patients with non-ischemic dilated cardiomyopathy following dapagliflozin initiation","volume":"76","author":"Hassan","year":"2024","journal-title":"Egypt Heart J"},{"key":"B24","doi-asserted-by":"publisher","first-page":"1192101","DOI":"10.3389\/fcvm.2023.1192101","article-title":"Implantable cardioverter defibrillator for primary prevention in patients with non-ischemic cardiomyopathy in the era of novel therapeutic agents- meta-analysis","volume":"10","author":"Kolben","year":"2023","journal-title":"Front Cardiovasc Med"}],"container-title":["Frontiers in Cardiovascular Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2025.1575493\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,12]],"date-time":"2025-09-12T05:34:57Z","timestamp":1757655297000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2025.1575493\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,12]]},"references-count":24,"alternative-id":["10.3389\/fcvm.2025.1575493"],"URL":"https:\/\/doi.org\/10.3389\/fcvm.2025.1575493","relation":{},"ISSN":["2297-055X"],"issn-type":[{"value":"2297-055X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,12]]},"article-number":"1575493"}}